基于网络药理学研究黄芪-半枝莲药对治疗肺癌机制

doi:10.3976/j.issn.1002-4026.2020.06.006

Abstract

Abstract: We aimed to determine the mechanism of Astragali Radix-Scutellariae Ｂarbatae Herba (AR-SBH) medicine in treating lung cancer. The active ingredient and target protein of the drug pair AR-SBH and lung cancer-related disease targets were searched through a database. The drug-compound-target and compound-target-disease networks were constructed. A protein-protein interaction(PPI) network of key targets was established, followed by analysis using R software for gene ontology(GO）and Kyoto Encyclopedia of Genes and Genomes(KEGG） key target enrichment. Sixteen effective active ingredients of the drug pair AR-SBH were obtained, which acted on 111 lung cancer-related targets. Key targets included TP53, AKT1, MAPK, TNF, VEGFA, and IL-6. GO enrichment analysis mainly involves RNA transcription, inflammation, extracellular, and nuclear. KEGG signaling pathway mainly includes TLR, NLR, HIF-1, FoxO, PI3K-Akt, and other pathways. AR-SBH plays a role in treating lung cancer by inhibiting inflammation, signal transduction, angiogenesis, and other processes. The results predict the molecular mechanism of AR-SBH in lung cancer treatment and lay a foundation for further in-depth study on the pharmacological effects of the drug pair AR-SBH.

Key words: Astragali Radix-Scutellariae Barbatae Herba; lung cancer, network pharmacology, tumor necrosis factor

CLC Number:

R285

HOU Yue, LI Qiang, WANG Dai-jie, CUI Li, ZHENG Xin. Mechanisms of the drug pair Astragali Radix-Scutellariae Barbatae Herba in treating lung cancer based on network pharmacology[J].Shandong Science, 2020, 33(6): 34-43.

References 36

1	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
2	SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics[J]. CA: A Cancer Journal for Clinicians, 2018, 68(1): 7-30. doi: 10.3322/caac.21442
3	郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28. doi: 10.3760/cma.j.issn.0253-3766.2019.01.008
4	杨清乐, 刘怀民. 中晚期肺癌治疗策略探讨及中医药优势分析[J]. 世界中西医结合杂志, 2016, 11(5): 725-728. doi: 10.13935/j.cnki.sjzx.160534
5	关念波, 刘浩, 林洪生. 肺癌中医药治疗的研究进展及展望[J]. 临床肿瘤学杂志, 2013, 18(3): 264-267. doi: 10.3969/j.issn.1009-0460.2013.03.017
6	张星星, 李泽庚. 肺癌中医病因病机探讨[J]. 中华中医药杂志, 2015, 30(10): 3447-3449.
7	郑川, 祝捷, 由凤鸣, 等. 肺癌的中医治法及方药使用规律研究[J]. 四川中医, 2016, 34(1): 217-219.
8	李道睿, 吴皓, 刘浩, 等. 基于信息挖掘技术总结林洪生辨治肺癌的临床用药规律[J]. 中医药导报, 2017, 23(23): 30-34. doi: 10.13862/j.cnki.cn43-1446/r.2017.23.009
9	蔡云, 陈远彬, 吴蕾, 等. 基于数据挖掘的刘伟胜治疗肺癌用药规律研究[J]. 河北中医, 2018, 40(8): 1132-1135. doi: 10.3969/j.issn.1002-2619.2018.08.003
10	杨冰, 于桂红, 李明雨, 等. 基于“补气固表”探究黄芪黄酮组分抑制C57BL/6荷瘤小鼠肿瘤生长及免疫调节机制研究[J]. 中国中药杂志, 2019, 44(23): 5184-5190. doi: 10.19540/j.cnki.cjcmm.20191104.401
11	王雪林, 李杨, 刘丹, 等. 黄芪多糖抑制黄嘌呤氧化酶诱导的肺癌A549细胞自噬并调节自噬相关蛋白的表达[J]. 细胞与分子免疫学杂志, 2019, 35(7): 619-624. doi: 10.13423/j.cnki.cjcmi.008841
12	刘小敏, 卢琳琳, 黄艳芳, 等. 黄芪水提物抑制PI3K/Akt通路预防肺癌发生的作用及机制研究[J]. 中草药, 2019, 50(7): 1621-1628. doi: 10.7501/j.issn.0253-2670.2019.07.019
13	WANG Q, ACHARYA N, LIU Z W, et al. Enhanced anticancer effects of Scutellaria barbata D. Don in combination with traditional Chinese medicine components on non-small cell lung cancer cells[J]. Journal of Ethnopharmacology, 2018, 217: 140-151. doi: 10.1016/j.jep.2018.02.020
14	SHIAU A L, SHEN Y T, HSIEH J L, et al.Scutellaria barbata inhibits angiogenesis through downregulation of HIF-1 α in lung tumor[J]. Environmental Toxicology, 2014, 29(4): 363-370. doi: 10.1002/tox.21763
15	Lab of Systems Pharmacology.TCMSP:Traditional Chinese Medicine systems pharmacology database and analysis platform[EB/OL].[2019-12-27].http://tcmspw.com/index.php.
16	张洁, 谭初兵, 徐为人. Lipinski五规则的研究进展[J]. 药物评价研究, 2011, 34(6): 451-455.
17	LIU H, WANG J, ZHOU W, et, al. Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice[J]. Ethnopharmacol, 2013, 146(3): 773-793. doi: 10.1016/j.jep.2013.02.004
18	MDI Biological Laboratory & NC State University .CTD: Comparative toxicogenomics database[EB/OL]. [2019-12-27]. http://ctdbase.org/.
19	Weizmann Institute of Science. GeneCards: The Human Gene Database[EB/OL]. [2019-12-27].https://www.genecards.org/.
20	Swiss Institute of Bioinformatics & Novo Nordisk Foundation Center Protein Research & European Molecular Biology Laboratory. STRING[EB/OL]. [2019-12-27]. https://string-db.org/.
21	顾浩, 陈寅萤, 王朋倩, 等. 基于熵值的冠心病基因网络模块划分方法评价与模块功能相似度分析[J]. 中国药理学与毒理学杂志, 2018, 32(5): 377-384. doi: 10.3867/j.issn.1000-3002.2018.05.005
22	纪立秋. 中医药对90例恶性肿瘤患者中医体质影响研究[J]. 亚太传统医药, 2016, 12(1): 96-98. doi: 10.11954/ytctyy.201601042
23	董永彩, 商亚珍. 半枝莲的药理学研究进展[J]. 承德医学院学报, 2009, 26(1): 98-100. doi: 10.3969/j.issn.1004-6879.2009.01.059
24	CHO Y Y, YAO K, PUGLIESE A, et al. A regulatory mechanism for RSK2 NH2-terminal kinase activity[J]. Cancer Research, 2009, 69(10): 4398-4406. doi: 10.1158/0008-5472.can-08-4959
25	LEE K M, LEE K W, JUNG S K, et al. Kaempferol inhibits UVB-induced COX-2 by suppressing Src kinase activity[J]. Biochemical Pharmacology, 2010, 80(12): 2042-2049. doi: 10.1016/j.bcp.2010.06.042
26	HUANG W W, TSAI S C, PENG S F, et al. Kaempferol induces autophagy through AMPK and AKT signaling molecules and causes G2/M arrest via downregulation of CDK1/cyclin B in SK-HEP-1 human hepatic cancer cells[J]. International Journal of Oncology, 2013, 42(6): 2069-2077. doi: 10.3892/ijo.2013.1909
27	KANG J W, KIM J H, SONG K, et al. Kaempferol and quercetin, components of Ginkgo biloba extract (EGb 761), induce caspase-3-dependent apoptosis in oral cavity cancer cells[J]. Phytotherapy Research, 2010, 24(S1): S77-S82. doi: 10.1002/ptr.2913
28	IMRAN M, RAUF A, SHAH Z A, et al. Chemo-preventive and therapeutic effect of the dietary flavonoid kaempferol: a comprehensive review[J]. Phytotherapy Research, 2019, 33(2): 263-275. doi: 10.1002/ptr.6227
29	TAY K C, TAN L T H, CHAN C K, et al. Formononetin: a review of its anticancer potentials and mechanisms[J]. Frontiers in Pharmacology, 2019, 10: 820. doi: 10.3389/fphar.2019.00820
30	李亮亮, 黄金智. 毛蕊异黄酮葡萄糖苷药理作用的研究进展[J]. 海南医学院学报,2020,26（2）:156-160. doi: 10.13210/j.cnki.jhmu.20191223.001
31	吕凤, 杜倩, 奚鑫, 等. 圣草酚药理作用研究进展[J]. 中草药, 2019, 50(23): 5907-5912. doi: 10.7501/j.issn.0253-2670.2019.23.036
32	康宝丽, 陆英, 徐增光. Toll样受体在肺癌中的研究进展[J]. 同济大学学报(医学版), 2015, 36(3): 140-144. doi: 10.16118/j.1008-0392.2015.03.031
33	KUTIKHIN A G. Role of NOD1/CARD4 and NOD2/CARD15 gene polymorphisms in cancer etiology[J]. Human Immunology, 2011, 72(10): 955-968. doi: 10.1016/j.humimm.2011.06.003
34	杨东霞, 项锋钢. HIF-1α在肺癌组织中表达的意义[J]. 青岛大学医学院学报, 2004, 40(1): 39-41. doi: 10.3969/j.issn.1672-4488.2004.01.014
35	罗娟, 周晓, 程志祥. FoxO1在非小细胞肺癌中的研究进展[J]. 南京医科大学学报(自然科学版), 2018, 38(8): 1161-1166. doi: 10.7655/NYDXBNS20180830
36	胡志英, 朱新江, 陈舒晨, 等. 非小细胞肺癌PI3K/AKT/MTOR信号通路的研究现状与进展[J]. 癌症进展, 2018, 16(6): 671-674. doi: 10.11877/j.issn.1672-1535.2018.16.06.02

Metrics

Comments

Recommended 0

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits third parties to freely share (i.e., copy and redistribute the material in any medium or format) and adapt (i.e., remix, transform, or build upon the material) the articles published in this journal, provided that appropriate credit is given, a link to the license is provided, and any changes made are indicated. The material may not be used for commercial purposes. For details of the CC BY-NC 4.0 license, please visit: https://creativecommons.org/licenses/by-nc/4.0

[1]	GUO Yingjian, YU Jinqian, DONG Hongjing, WANG Chuangchuang, ZHONG Kai, WANG Xiao. Topological analysis reveals mechanism of Panax notoginseng saponin in the treatment of gouty arthritis based on network pharmacology and in vitro experiments [J]. Shandong Science, 2025, 38(5): 40-48.
[2]	SUN Jingtian, LIU Feng, ZHANG Zhe, ZHANG Yufu, MA Xinhui, LI Qingjun, WANG Xiao, DONG Hongjing. Exploring the medication rule of Chrysanthemum morifolium Ramat. and investigating the synergistic pharmacological activity of core combination herbs [J]. Shandong Science, 2025, 38(1): 1-8.
[3]	HAN Huijie, LIU Hui, ZHAO Yongbo, WANG Songpo. A study based on network pharmacology and experimental verification exploring the mechanism of quercetin against colorectal cancer through the p53 signaling pathway [J]. Shandong Science, 2025, 38(1): 32-43.
[4]	FAN Wei, SHEN Chuanlin, ZHANG Xuanming, DU Xingshuo, ZHAN Wen, SUN Chen, JIN Meng, LI Xiaobin, ZHANG Sichen, SUN Botong, HE Qiuxia. Prediction of anti-aging mechanism of Panax quinquefolius L. by network pharmacology and molecular docking [J]. Shandong Science, 2024, 37(6): 42-50.
[5]	YAN Jin, LI Fei, WU Keming, YANG Haobo. The molecular mechanisms by which Xinjia Cistanche Tusi Decoction promotes follicular development through mitophagy [J]. Shandong Science, 2024, 37(5): 25-34.
[6]	LIN Shenghua, XUE Chang, MA honglin, FAN Wei, SHEN Chuanlin, CHEN Jiayu, SUN Botong, DU Xingshuo, ZHAN Wen, LI Xiaobin, ZHANG Shanshan, JIN Meng, HE Qiuxia. Study of the active components and mechanism of action of antithrombotic Xuefuzhuyu oral liquid based on network pharmacology and molecular docking technology [J]. Shandong Science, 2024, 37(4): 26-33.
[7]	MA Shijing, HE Chunyan, GUAN Tianzhu, YAO Xueshuang, ZHANG Junpeng. Exploration of antihyperlipidemia mechanism of Monopterus albus peptides based on hyperlipidemic zebrafish model and network pharmacology [J]. Shandong Science, 2024, 37(3): 27-38.
[8]	WEI Zekun, YANG Yujie, LIU Shuang, WANG Yan, DONG Hongjing, LIU Chunmei. Reverse mining of Chinese medicine for intervention of liver cancer based on GEO database combined with network pharmacology and molecular docking technology [J]. Shandong Science, 2024, 37(3): 39-47.
[9]	LIU Kechun, WANG Yongcheng, ZANG Xiaohan, XIA Qing, ZHANG Yun, ZHANG Shanshan, SUN Chen. Advancements in network pharmacology and zebrafish modeling for studying traditional Chinese medicine’s effective substances and mechanisms of action [J]. Shandong Science, 2024, 37(2): 29-35.
[10]	FU Zhaoju, CHENG Guo, LIN Dengmei, LI Jun, ZHANG Nannan. Experimental study and network pharmacological analysis of the anti-inflammatory action mechanism of Mahonia bealei (Fort.) Carr. [J]. Shandong Science, 2024, 37(1): 24-31.
[11]	CHEN Chun, QI Daqing, PAN Jingwen. Clinical significance of stromal cell score in gastric cancer and intervention with Weifuchun capsules [J]. Shandong Science, 2023, 36(6): 38-47.
[12]	MU Nana, LIAO Binbin, LI Zhen, LI Jipin, LI Yihua, WANG Ying, CHEN Xubing. Investigating the mechanism of action of Elephantopus scaber L. in the treatment of ulcerative colitis based on network pharmacology and molecular docking [J]. Shandong Science, 2023, 36(6): 48-55.
[13]	WANG Yifan, ZHANG Zhe, TIAN Caijun. Mechanism of Sanhuang Xiexin decoction in treatment of Alzheimer's disease based on network pharmacology and molecular docking method [J]. Shandong Science, 2023, 36(5): 19-26.
[14]	FU Mengya, AO Huihao, BU Chao, PENG Tangyi, WU Deling, HAN Yanquan, HONG Yan. Forecast analysis of the quality markers of Zingiberis Rhizoma based on fingerprints and network pharmacology [J]. Shandong Science, 2023, 36(4): 35-41.
[15]	YIN Zhipeng, GAO Yunyun, LIU Wenwen, GUO Pengbo, ZHAO Yinghui. Exploring the mechanism of Xiangsha Liujunzi Decoction in treating Helicobacter pylori-associated gastritis based on network pharmacology and molecular docking technology [J]. Shandong Science, 2023, 36(4): 52-60.

Mechanisms of the drug pair Astragali Radix-Scutellariae Barbatae Herba in treating lung cancer based on network pharmacology

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 36

Related Articles 15

Metrics

Comments

Recommended 0